Preclinical News and Research

RSS

OncoGenex Pharmaceuticals receives grant funding for Phase 2 clinical trial of OGX-427

OncoGenex Pharmaceuticals, Inc., today announced that a randomized, controlled, investigator-sponsored Phase 2 clinical trial evaluating OGX-427 when administered as a monotherapy to patients with castrate resistant prostate cancer (CRPC) has received grant funding.

6 Jan 2010

Patient enrolled in Phase I clinical study of two investigational compounds: MK-2206 and AZD6244

Dr. Anthony Tolcher, clinical director for South Texas Accelerated Research Therapeutics (START) at the START Center for Cancer Care in San Antonio, announced today that the first patient has been enrolled in a groundbreaking Phase I clinical trial of a novel combination anticancer regimen composed of two investigational compounds: MK-2206 from Merck & Co., Inc. and AZD6244 (ARRY-886*) from AstraZeneca.

6 Jan 2010

AMT receives Innovation Credit to develop gene therapy treatment for DMD

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that it will receive an Innovation Credit of up to EUR 4 million from the Dutch government to support the development of AMT's gene therapy treatment for Duchenne Muscular Dystrophy (DMD).

6 Jan 2010

Phase I clinical trial for Intellikine's INK128 inhibitor initiated

Intellikine, Inc. has initiated a Phase I clinical trial for its targeted anticancer drug INK128, a novel orally-available small molecule inhibitor of both the TORC1 and TORC2 complexes, key components of the PI3K/mTOR signaling pathway.

6 Jan 2010

New research may yield more effective treatment for childhood leukemia

A team of Israeli scientists at the Sheba Medical Center's Research Center for Leukemia and Childhood Malignancies has discovered a method for developing a more effective and less perilous treatment for those suffering from childhood leukemia, the most common cancer in children.

6 Jan 2010

Preclinical data of Geron's telomerase inhibitor drug published

Geron Corporation today announced the publication of preclinical data demonstrating that its telomerase inhibitor drug, imetelstat (GRN163L), inhibited telomerase activity and reduced tumor size in xenograft models of glioblastoma, and inhibited the activity of glioblastoma stem cells in culture.

6 Jan 2010

Cancer Research UK and CRT to undertake phase I clinical trial of DI-B4

CANCER RESEARCH UK and Cancer Research Technology (CRT), the charity's development and commercialisation arm, are to undertake a phase I clinical trial of an investigational monoclonal antibody1 drug from Merck KGaA, Darmstadt, Germany, called DI-B4 - it is announced today (Monday).

6 Jan 2010

Bioject Medical Technologies collaborates with MPI Research to explore drug and device opportunities

Bioject Medical Technologies Inc. (OTCBB:BJCT), a leading developer of needle-free injection therapy systems, today announced that it has established a strategic alliance with MPI Research, a leading pre-clinical research organization with experience in the development of injectable therapeutics.

5 Jan 2010

Phase 2 study evaluating VBL Therapeutics' lead compound VB-201 initiated

VBL Therapeutics today announced the initiation of a Phase 2 efficacy and safety study evaluating lead compound VB-201 for the treatment of patients with psoriasis. VB-201 is poised to be a first-in-class, orally-administered immune response modifier expected to reduce inflammation in a broad range of conditions such as psoriasis.

5 Jan 2010

FDA approves minimally invasive procedure for treating benign and malignant tumors

A minimally invasive surgical approach developed by head and neck surgeons at the University of Pennsylvania School of Medicine has been cleared by the U.S. Food and Drug Administration (FDA). The

5 Jan 2010

CBI signs definitive share purchase agreement to acquire GL Biochem

Commonwealth Biotechnologies, Inc. (“CBI”) is pleased to announced it has entered into a revised and binding definitive share purchase agreement to acquire the parent of Shanghai-based GL

4 Jan 2010

BioInvent International begins BI-505 drug study on patients with advanced multiple myeloma

BioInvent International AB announced today that the first patient has been treated in an open, dose-escalation phase I study of the company’s antibody BI-505 for patients with advanced multiple myeloma.

4 Jan 2010

Experimental lung cancer drug promising against brain cancer glioblastoma and prostate cancer

An experimental drug currently being tested against breast and lung cancer shows promise in fighting the brain cancer glioblastoma and prostate cancer, researchers at UT Southwestern Medical Center have found in two preclinical studies.

4 Jan 2010

Santarus submits rifamycin SV MMX IND to the FDA

Santarus, Inc., a specialty biopharmaceutical company, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) requesting approval to begin a Phase III clinical program evaluating rifamycin SV MMX® in patients with travelers’ diarrhea.

30 Dec 2009

Advances in development of “lipidoid” formulations for systemic delivery of RNAi therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators from the David H. Koch Institute for Integrative Research at the Massachusetts Institute of Technology (MIT) today announced the publication of new data in the journal Proceedings of the National Academy of Sciences (PNAS) describing further advancements in discovery and development of novel “lipidoid” formulations for the systemic delivery of RNAi therapeutics.

30 Dec 2009

TRAP-1 may prevent cancer cell death, current research suggests

Current research suggests that TNF-receptor associated protein-1 (TRAP-1) may prevent cancer cell death. The related report by Leav et al, "Cytoprotective Mitochondrial Chaperone TRAP-1 as a Novel Molecular Target in Localized and Metastatic Prostate Cancer," appears in the January 2010 issue of the American Journal of Pathology.

30 Dec 2009

Emerald BioStructures engineers new allosteric small molecule modulators of the PDE4 enzyme

Emerald BioStructures (formerly deCODE biostructures) announced today a publication in the December 27, 2009 advance online issue of Nature Biotechnology, detailing the application of structure-based drug design (SBDD) to engineer new allosteric small molecule modulators of the enzyme phosphodiesterase-4 (PDE4), with reduced side effects. According to the paper, the researchers established the structural basis of PDE4 regulation through crystal structures of the PDE4 regulatory domain in contact with small molecules.

29 Dec 2009

SVA submits the first clinical trial application for HFMD vaccine in China

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that it has filed the application with China's State Food and Drug Administration (SFDA) to commence a human clinical trial for its vaccine against human enterovirus 71 (EV 71), which causes hand, foot, and mouth disease (HFMD). This is the first clinical trial application for HFMD vaccine submitted in China.

28 Dec 2009

Publication validates company's structure-based approach for addressing undruggable targets

28 Dec 2009

SemBioSys Genetics' Apo AI(Milano) program progress update

SemBioSys Genetics Inc. provided an update today on its progress on plant-produced Apo AI(Milano) in light of the Apo AI(Milano) license agreement between Pfizer Inc. and The Medicines Company, of Parsippany, New Jersey.

24 Dec 2009

Preclinical News and Research

OncoGenex Pharmaceuticals receives grant funding for Phase 2 clinical trial of OGX-427

Patient enrolled in Phase I clinical study of two investigational compounds: MK-2206 and AZD6244

AMT receives Innovation Credit to develop gene therapy treatment for DMD

Phase I clinical trial for Intellikine's INK128 inhibitor initiated

New research may yield more effective treatment for childhood leukemia

Preclinical data of Geron's telomerase inhibitor drug published

Cancer Research UK and CRT to undertake phase I clinical trial of DI-B4

Bioject Medical Technologies collaborates with MPI Research to explore drug and device opportunities

Phase 2 study evaluating VBL Therapeutics' lead compound VB-201 initiated

FDA approves minimally invasive procedure for treating benign and malignant tumors

CBI signs definitive share purchase agreement to acquire GL Biochem

BioInvent International begins BI-505 drug study on patients with advanced multiple myeloma

Experimental lung cancer drug promising against brain cancer glioblastoma and prostate cancer

Santarus submits rifamycin SV MMX IND to the FDA

Advances in development of “lipidoid” formulations for systemic delivery of RNAi therapeutics

TRAP-1 may prevent cancer cell death, current research suggests

Emerald BioStructures engineers new allosteric small molecule modulators of the PDE4 enzyme

SVA submits the first clinical trial application for HFMD vaccine in China

Publication validates company's structure-based approach for addressing undruggable targets

SemBioSys Genetics' Apo AI(Milano) program progress update

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News